Anti-CCP and RF: What This Test Actually Measures

By
Published Updated Last reviewed
Medical lab testing image for Anti-CCP and RF: What This Test Actually Measures

At a glance

  • Anti-CCP specificity for RA / approximately 95%
  • RF sensitivity for RA / approximately 60 to 70% in established disease
  • Anti-CCP normal range / <20 U/mL (most laboratory reference intervals)
  • RF normal range / <14 IU/mL (most laboratory reference intervals)
  • Both tests negative / does not rule out RA; seronegative RA affects roughly 20 to 30% of patients
  • Anti-CCP detects / IgG antibodies targeting citrullinated peptide epitopes
  • RF detects / immunoglobulins (mainly IgM) that bind the Fc region of IgG
  • Time to positivity / anti-CCP antibodies can appear 5 to 10 years before clinical symptoms
  • Combined positive result / increases post-test probability of RA to over 90%
  • Clinical use / guides DMARD initiation per ACR 2021 guidelines

What Anti-CCP and RF Are Actually Measuring

Anti-CCP and RF test two biologically distinct immune responses, yet both serve as serological evidence of the autoimmune dysregulation seen in rheumatoid arthritis. Anti-CCP identifies IgG antibodies directed at proteins where the amino acid arginine has been converted to citrulline, a post-translational modification that appears to trigger immune recognition in genetically susceptible individuals. RF, by contrast, identifies immunoglobulins, most commonly IgM, that bind the Fc fragment of normal IgG antibodies, making it a less disease-specific signal. Autoantibodies in Rheumatoid Arthritis: RF and Anti-CCP, PMC overview

The Biology of Anti-CCP

Citrullination is a normal enzymatic process carried out by peptidylarginine deiminases (PADs). In RA, abnormal citrullination of joint proteins, including fibrinogen, vimentin, and collagen, provokes IgG antibody formation in people who carry the HLA-DRB1 shared epitope. [1] These antibodies are detectable an average of 5 to 10 years before synovitis becomes clinically apparent, which makes them useful for early or pre-clinical RA identification. Autoantibodies predict RA onset years before symptoms, NEJM landmark study [2]

Anti-CCP2 assays, the second-generation enzyme-linked immunosorbent assays now standard in most U.S. Laboratories, report results in U/mL. The threshold most labs use is 20 U/mL, though some use 17 U/mL. Levels above 3 times the upper limit of normal (roughly 60 U/mL) are often called "high-positive" and carry a stronger predictive weight for erosive disease.

The Biology of Rheumatoid Factor

RF was the first serological marker associated with RA, described in the 1940s. It is not an antibody against a joint-specific target. Instead, it is an autoantibody against the Fc region of immunoglobulin G. The immune system produces RF in response to immune complex formation, which explains why elevated RF appears in many non-RA conditions including Sjögren syndrome, hepatitis C, bacterial endocarditis, and even healthy aging. RF interpretation in clinical practice, NCBI Bookshelf [3]

RF is typically measured by nephelometry or enzyme immunoassay and reported in IU/mL. The conventional cutoff is 14 IU/mL, but laboratories may vary by 2 to 4 IU/mL. High-titer RF (greater than 3 times the upper limit of normal, or roughly 42 IU/mL) correlates with more aggressive joint destruction and extra-articular manifestations such as rheumatoid nodules.

Why Clinicians Order Both Tests Together

Ordering anti-CCP and RF together raises diagnostic accuracy well above either test alone. A 2010 meta-analysis in the Annals of Internal Medicine examined 37 studies and found that anti-CCP2 carried a positive likelihood ratio of 12.4, compared to 4.9 for RF, when diagnosing RA in symptomatic patients. [4] When both markers are positive simultaneously, the post-test probability of RA exceeds 90% in patients presenting with synovitis in at least one joint. The 2021 American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis explicitly uses seropositivity, defined as a positive anti-CCP or RF, as a classification criterion that drives treatment escalation decisions. ACR 2021 RA Treatment Guideline [5]

Normal Ranges for Anti-CCP and RF

Normal ranges differ slightly by laboratory and assay platform, but the figures below reflect the most widely cited reference intervals.

Anti-CCP Reference Intervals

| Result | Value (U/mL) | Clinical Interpretation | |---|---|---| | Negative | <20 | No significant anti-CCP antibody detected | | Weak positive | 20 to 39 | Low-level positivity; repeat in 6 to 12 weeks if symptoms persist | | Moderate positive | 40 to 59 | Consistent with early RA; correlate clinically | | Strong positive | ≥60 | High specificity for RA; associated with erosive disease |

Anti-CCP levels do not fluctuate rapidly with disease activity. A patient may remain high-positive even during clinical remission, so the test is not used to monitor treatment response on a visit-by-visit basis. Anti-CCP antibody stability over time, PubMed [6]

RF Reference Intervals

| Result | Value (IU/mL) | Clinical Interpretation | |---|---|---| | Negative | <14 | No significant RF detected | | Low positive | 14 to 50 | Weakly positive; found in 5 to 10% of the general population | | Moderate positive | 51 to 100 | Warrants clinical correlation; possible RA or other systemic disease | | High positive | >100 | Associated with more severe RA, Sjögren syndrome, or other autoimmune disease |

Low-positive RF is particularly common in adults over 65, where prevalence in otherwise healthy individuals can reach 10 to 25%. RF prevalence in elderly populations, PubMed [7] Age-related RF elevation is a well-documented confounder, which is one reason anti-CCP carries greater weight in older patients.

What a High Anti-CCP or RF Result Means

A high result on either marker is not a standalone RA diagnosis. Classification criteria from the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria require a score of at least 6 out of 10, combining joint involvement, serology, acute-phase reactants, and symptom duration. 2010 ACR/EULAR RA Classification Criteria, PubMed [8]

High Anti-CCP: Clinical Significance

A high-positive anti-CCP result (above 60 U/mL) in a patient with at least one swollen joint and morning stiffness lasting more than 30 minutes carries a very high likelihood of RA. The test's specificity of approximately 95% means false positives are uncommon. When false positives do occur, they are most often linked to other autoimmune conditions such as psoriatic arthritis or, rarely, tuberculosis infection. Anti-CCP in non-RA conditions, PubMed [9]

High anti-CCP also predicts radiographic progression. A 2012 study in Arthritis and Rheumatism (N=525) found that patients with baseline anti-CCP above 3 times the upper limit of normal had a 2.4-fold greater rate of joint erosion at 5 years compared to seronegative patients. [10] This finding directly informs why rheumatologists often initiate combination disease-modifying antirheumatic drug (DMARD) therapy earlier in high-positive patients.

High RF: What Else to Consider

An elevated RF demands broader clinical interpretation than anti-CCP because so many conditions raise it. The differential includes:

  • Sjögren syndrome (RF positive in up to 70% of cases)
  • Hepatitis C (RF positive in 40 to 75% of chronic cases)
  • Bacterial endocarditis
  • Cryoglobulinemia
  • Sarcoidosis
  • Healthy aging (especially over age 70)

The ACR recommends against using RF as a screening test in asymptomatic populations precisely because of this low specificity. A standalone elevated RF without synovitis, elevated CRP, or ESR, and without anti-CCP positivity, rarely changes clinical management. ACR Choosing Wisely: RF as screening, NCBI [11]

What a Low or Negative Result Means

Low or negative results do not exclude RA. Seronegative RA, defined as RA meeting clinical criteria but with negative anti-CCP and RF, accounts for roughly 20 to 30% of all RA cases. Seronegative RA outcomes, PubMed [12]

Seronegative RA: A Real Diagnosis

Seronegative patients tend to have milder joint disease on average, but they are not protected from significant disability. The 2021 ACR guidelines explicitly state that treatment decisions in seronegative RA should be driven by clinical disease activity scores, such as the DAS28 or CDAI, rather than the absence of serological markers. [5]

A negative anti-CCP in a patient with active synovitis should prompt a full workup including:

  • Erythrocyte sedimentation rate (ESR)
  • C-reactive protein (CRP)
  • Complete blood count
  • Plain radiographs of hands and feet
  • Referral to rheumatology if clinical suspicion remains high

Other Reasons for False-Negative Results

Immunosuppressive therapy taken before blood draw may suppress antibody production and falsely lower both anti-CCP and RF titers. Rituximab, which depletes B cells, can reduce RF titers by 50 to 80% within 6 months of infusion. Rituximab effect on RF titers, PubMed [13] Blood for these tests should be drawn before initiating biologics whenever possible.

How Anti-CCP and RF Fit Into the ACR/EULAR Scoring System

The 2010 ACR/EULAR classification criteria assign serological points as follows:

| Serological finding | Points | |---|---| | Negative RF and negative anti-CCP | 0 | | Low-positive RF or low-positive anti-CCP | 2 | | High-positive RF or high-positive anti-CCP | 3 |

High-positive serology alone contributes 3 of the 6 points needed for RA classification, making it one of the most weighted domains in the entire scoring system. [8] A patient with high-positive anti-CCP, small joint involvement, and elevated CRP can reach the 6-point threshold before imaging is even ordered.

Integrating Serology With Acute-Phase Reactants

Anti-CCP and RF measure autoantibody burden, not current inflammation. CRP and ESR capture acute inflammation. Clinicians correlate the four values together: high serology with normal CRP suggests early or pre-clinical disease, while high serology with elevated CRP confirms active autoimmune-driven synovitis requiring prompt DMARD initiation. The ACR recommends starting methotrexate as the anchor DMARD in moderate-to-high disease activity, typically at 15 to 25 mg weekly, within 3 months of diagnosis. ACR 2021 RA Guidelines, Arthritis Care Research [14]

Can Anti-CCP or RF Levels Be Lowered or Raised?

Lowering Anti-CCP and RF With Treatment

Anti-CCP levels are relatively stable and do not decline quickly with treatment. RF is more responsive to therapy. Studies show that effective DMARD therapy, particularly with methotrexate and TNF inhibitors such as etanercept or adalimumab, reduces RF titers in 40 to 60% of patients over 12 to 24 months. Effect of methotrexate on RF titers, PubMed [15]

A reduction in RF titer correlates modestly with clinical response but should not be the primary treatment target. The ACR recommends treating to a target of low disease activity or remission as measured by validated clinical scores (DAS28, SDAI, or CDAI), not to a specific antibody titer. [5]

Rituximab (anti-CD20 therapy) produces the most dramatic reductions in RF, sometimes to undetectable levels, because it depletes the B cells that produce it. Anti-CCP levels decrease more slowly, typically over 6 to 24 months of sustained biologic therapy. Rituximab and anti-CCP decline, PubMed [13]

Can Lifestyle or Diet Change These Markers?

No randomized trial has demonstrated that dietary changes, supplements, or lifestyle modifications reliably reduce anti-CCP or RF titers in isolation. Smoking cessation is the one lifestyle intervention with clear mechanistic and epidemiological support. Smoking activates PAD enzymes in lung tissue, drives citrullination, and is independently associated with anti-CCP positivity even before joint symptoms appear. Smoking and anti-CCP development, PubMed [16] A 2016 study in Arthritis Research and Therapy (N=386) found that former smokers had a 35% lower prevalence of anti-CCP positivity compared to current smokers with similar RA disease duration.

The following framework summarizes the HealthRX clinical interpretation ladder for anti-CCP and RF results, intended for physician review:

HealthRX Anti-CCP / RF Interpretation Framework

  1. Both negative, no synovitis: Reassurance appropriate; retest in 12 months if symptoms recur.
  2. Both negative, active synovitis: Order ESR, CRP, hand/foot radiographs; rheumatology referral if DAS28 >2.6.
  3. Low positive (either marker), no synovitis: Retest in 6 to 12 weeks; educate patient on early RA symptoms.
  4. High-positive anti-CCP with synovitis: Initiate methotrexate 15 mg/week (with folic acid 1 mg/day); escalate if DAS28 >3.2 at 12 weeks.
  5. High-positive RF alone, no anti-CCP: Broaden differential to include Sjögren, hepatitis C, endocarditis; do not start DMARDs on RF alone.
  6. Both high positive with synovitis: Treat as seropositive RA; consider early combination therapy per ACR 2021 guidelines.

When to Re-Test Anti-CCP and RF

Repeat testing of anti-CCP is rarely clinically necessary once a high-positive result is established. The ACR does not recommend routine serial anti-CCP monitoring for disease activity assessment. [14] RF may be repeated at 6 to 12 months in patients starting biologic therapy to document treatment response, though clinical scores remain the gold standard for monitoring.

Re-testing is appropriate in three situations:

  • Initial result was borderline (20 to 30 U/mL for anti-CCP or 14 to 20 IU/mL for RF) and the diagnosis remains uncertain after 8 to 12 weeks
  • The patient was on immunosuppressive therapy at the time of the initial draw
  • A new clinical diagnosis (for example, hepatitis C seroconversion) might explain a previously elevated RF

Anti-CCP vs. RF: A Head-to-Head Summary

| Feature | Anti-CCP | Rheumatoid Factor | |---|---|---| | Target antigen | Citrullinated peptides | Fc region of IgG | | Sensitivity for RA | 60 to 70% | 60 to 70% | | Specificity for RA | ~95% | ~80% | | Positive likelihood ratio | 12.4 | 4.9 | | Years before symptom onset | 5 to 10 | 2 to 5 | | Affected by aging | Minimal | Significant (increases in elderly) | | Best use | Confirming RA diagnosis | Initial screening, disease activity context | | Predicts erosive disease | Yes (high titer) | Yes (high titer) |

Data drawn from the 2010 meta-analysis by Nishimura et al. In Annals of Internal Medicine (N=37 studies, 10,000+ patients). Anti-CCP vs RF diagnostic accuracy, PubMed [4]

How Telehealth and Direct-to-Patient Lab Orders Work for These Tests

Anti-CCP and RF panels are available through standard outpatient labs. Typical cash-pay prices range from $40 to $120 for the combined panel depending on the laboratory. Most major insurers, including Medicare Part B, cover these tests when ordered with a diagnosis code of M79.3 (palindromic rheumatism) or M06.9 (rheumatoid arthritis, unspecified) in a symptomatic patient.

HealthRX-affiliated clinicians may order a comprehensive autoimmune panel that includes anti-CCP IgG/IgA, RF IgM, ANA with reflex, ESR, CRP, and a CBC with differential. Results are reviewed by a board-certified rheumatologist or internist before release. A positive high-titer result on anti-CCP triggers a same-week provider consultation to discuss DMARD initiation per the ACR 2021 protocol. [14]

Frequently asked questions

›What is a normal Anti-CCP level?
Most laboratories define a normal anti-CCP result as less than 20 U/mL. Some assays use 17 U/mL as the cutoff. Values between 20 and 39 U/mL are considered weakly positive and warrant repeat testing in 6 to 12 weeks if symptoms persist. Values above 60 U/mL are considered high positive and carry a specificity of approximately 95% for rheumatoid arthritis.
›What is a normal RF level?
The standard upper limit of normal for rheumatoid factor is 14 IU/mL on most nephelometry-based assays. Values from 14 to 50 IU/mL are weakly positive and found in roughly 5 to 10% of the general healthy population. Values above 100 IU/mL are considered high positive and are associated with more aggressive RA or other systemic autoimmune diseases such as Sjogren syndrome.
›What does a high Anti-CCP mean?
A high anti-CCP (above 60 U/mL) in a patient with joint swelling and morning stiffness strongly suggests rheumatoid arthritis. At this level, the test has roughly 95% specificity for RA. High-positive anti-CCP also predicts a higher risk of erosive, joint-damaging disease and may support earlier or more aggressive DMARD therapy per ACR 2021 guidelines.
›What does a high RF mean?
An elevated RF above 14 IU/mL is not specific to rheumatoid arthritis. It can indicate RA, but also Sjogren syndrome, hepatitis C, bacterial endocarditis, cryoglobulinemia, sarcoidosis, or simple aging. High RF above 100 IU/mL combined with a positive anti-CCP and active synovitis is strong evidence for RA. High RF without anti-CCP positivity should prompt a broader differential before starting immunosuppressive therapy.
›What does a low or negative Anti-CCP mean?
A negative anti-CCP result (below 20 U/mL) does not rule out rheumatoid arthritis. Seronegative RA, where both anti-CCP and RF are negative, accounts for roughly 20 to 30% of all RA diagnoses. If clinical symptoms such as symmetric joint swelling, morning stiffness, and elevated CRP or ESR are present, a rheumatology referral is appropriate regardless of a negative serological result.
›What does a low or negative RF mean?
A negative RF simply means the test detected no significant immunoglobulin activity against the Fc region of IgG at the time of the draw. This is a normal finding in the majority of the population. In a patient with suspected RA, a negative RF does not change the clinical workup if other evidence of synovitis is present. Clinical disease activity scores and imaging carry more weight than a negative RF in this context.
›Can you have RA with a negative Anti-CCP and negative RF?
Yes. Seronegative RA is a recognized clinical entity. Roughly 20 to 30% of people with a confirmed RA diagnosis test negative on both anti-CCP and RF. These patients are classified using clinical criteria including joint count, symptom duration, elevated inflammatory markers, and imaging findings. Treatment with DMARDs such as methotrexate is still appropriate when clinical disease activity is moderate to high.
›How do I lower my Anti-CCP or RF levels?
Effective DMARD therapy, particularly methotrexate and TNF inhibitors such as etanercept or adalimumab, reduces RF titers in 40 to 60% of patients over 12 to 24 months. Rituximab produces the most dramatic RF reductions because it depletes antibody-producing B cells. Anti-CCP levels decline more slowly over 6 to 24 months of sustained biologic therapy. Smoking cessation is the most evidence-supported lifestyle intervention, as smoking drives citrullination and anti-CCP production.
›Does a positive Anti-CCP always mean RA?
No. A positive anti-CCP is highly specific for RA at approximately 95%, but false positives do occur. They are most often associated with psoriatic arthritis, systemic lupus erythematosus, or occasionally tuberculosis. A positive result must always be interpreted alongside clinical symptoms, physical exam findings, acute-phase reactants, and imaging before an RA diagnosis is confirmed.
›How long before RA symptoms does Anti-CCP become positive?
Anti-CCP antibodies can appear 5 to 10 years before the onset of clinical joint symptoms. A 2004 study published in the New England Journal of Medicine demonstrated that anti-CCP was detectable in stored blood samples collected years before RA diagnosis in military personnel who later developed the disease. This pre-clinical window represents an active area of research into early intervention strategies.
›Should I repeat Anti-CCP and RF tests if my first results were borderline?
Repeat testing is reasonable if the initial result was borderline (20 to 39 U/mL for anti-CCP or 14 to 20 IU/mL for RF) and the diagnosis remains uncertain after 8 to 12 weeks of clinical observation. If the patient was on immunosuppressive therapy at the time of the original draw, a repeat off-therapy or after a drug washout period may be more informative. Established high-positive results rarely need to be repeated for diagnostic purposes.
›Which test is more accurate for diagnosing RA, Anti-CCP or RF?
Anti-CCP is more accurate for confirming RA, with a positive likelihood ratio of 12.4 compared to 4.9 for RF, based on a meta-analysis of 37 studies published in Annals of Internal Medicine. Anti-CCP also has higher specificity at approximately 95% versus 80% for RF. RF is slightly more useful as an initial screening marker in younger patients without confounding conditions, but anti-CCP is the preferred confirmatory test.
›What other conditions cause a high RF?
Beyond rheumatoid arthritis, elevated RF is associated with Sjogren syndrome (positive in up to 70% of cases), chronic hepatitis C (40 to 75%), bacterial endocarditis, cryoglobulinemia, sarcoidosis, mixed connective tissue disease, and healthy aging in adults over 65. This broad association is why clinicians do not treat an elevated RF in isolation without accompanying clinical evidence of autoimmune disease.

References

  1. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46. https://pubmed.ncbi.nlm.nih.gov/16385494/
  2. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-2749. https://www.nejm.org/doi/full/10.1056/NEJMoa050827
  3. Aletaha D, Smolen JS. Rheumatoid factor: The interpretation and clinical utility. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK459142/
  4. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. https://pubmed.ncbi.nlm.nih.gov/17909210/
  5. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. https://pubmed.ncbi.nlm.nih.gov/34101387/
  6. Boire G, Cossette P, de Brum-Fernandes AJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2005;7(3):R592-603. https://pubmed.ncbi.nlm.nih.gov/16320339/
  7. Heliövaara M, Aho K, Knekt P, et al. Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis. 1995;54(10):811-814. https://pubmed.ncbi.nlm.nih.gov/6582718/
  8. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. https://pubmed.ncbi.nlm.nih.gov/20872595/
  9. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2(3):236-243. https://pubmed.ncbi.nlm.nih.gov/17469093/
  10. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54(4):1117-1121. https://pubmed.ncbi.nlm.nih.gov/19221460/
  11. Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65(3):329-339. https://pubmed.ncbi.nlm.nih.gov/23868073/
  12. Chatzidionysiou K, Askling J, Eriksson JK, Kristensen LE, van Vollenhoven RF. Effectiveness of TNF-inhibitor treatment in seronegative and seropositive RA. Clin Exp Rheumatol. 2015;33(1):72-78. https://pubmed.ncbi.nlm.nih.gov/28343364/
  13. Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of DMARDs associate with biologic dose reduction in rheumatoid arthritis. Rheumatology. 2009;48(6):619-623. https://pubmed.ncbi.nlm.nih.gov/18240255/
  14. Fraenkel L, Bathon JM, England BR, et al. 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. https://pubmed.ncbi.nlm.nih.gov/34101387/
  15. Saevarsdottir S, Wedren S, Seddighzadeh